MX2020014124A - Preparacion de aptameros. - Google Patents
Preparacion de aptameros.Info
- Publication number
- MX2020014124A MX2020014124A MX2020014124A MX2020014124A MX2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A MX 2020014124 A MX2020014124 A MX 2020014124A
- Authority
- MX
- Mexico
- Prior art keywords
- aptamer
- preparation
- aptamers
- fgf2
- asset
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018124390 | 2018-06-29 | ||
| PCT/JP2019/025766 WO2020004607A1 (ja) | 2018-06-29 | 2019-06-28 | アプタマー製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020014124A true MX2020014124A (es) | 2021-05-31 |
Family
ID=68986754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020014124A MX2020014124A (es) | 2018-06-29 | 2019-06-28 | Preparacion de aptameros. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210269802A1 (enExample) |
| EP (1) | EP3815715B1 (enExample) |
| JP (1) | JP7340264B2 (enExample) |
| KR (1) | KR102841342B1 (enExample) |
| CN (1) | CN112384246B (enExample) |
| AU (1) | AU2019292134B2 (enExample) |
| BR (1) | BR112020026634A2 (enExample) |
| CA (1) | CA3105002A1 (enExample) |
| ES (1) | ES2992308T3 (enExample) |
| IL (1) | IL279595B1 (enExample) |
| MX (1) | MX2020014124A (enExample) |
| SG (1) | SG11202012933QA (enExample) |
| TW (1) | TWI845521B (enExample) |
| WO (1) | WO2020004607A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021157681A1 (ja) | 2020-02-06 | 2021-08-12 | 株式会社リボミック | 網膜下高反射病巣または網膜下高反射病巣を伴う網膜疾患の治療剤 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5847086A (en) * | 1991-06-20 | 1998-12-08 | Centeon L.L.C. | Therapeutic fragments of von Willebrand factor |
| MY147374A (en) * | 2006-11-14 | 2012-11-30 | Ribomic Inc | Aptamer against midkine and use thereof |
| CN101317820B (zh) * | 2007-04-19 | 2012-02-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 生物亲和性配体分子介导的靶向脂质体，其制 备及其应用 |
| US20090203766A1 (en) * | 2007-06-01 | 2009-08-13 | Archemix Corp. | vWF aptamer formulations and methods for use |
| WO2009118108A1 (en) * | 2008-03-26 | 2009-10-01 | Merck Patent Gmbh | Method of long term storage of substrate-coupled beads |
| US9052323B2 (en) * | 2009-08-27 | 2015-06-09 | The University Of Kansas | Osmolyte mixture for protein stabilization |
| JP5899550B2 (ja) | 2010-02-12 | 2016-04-06 | 株式会社リボミック | Ｆｇｆ２に対するアプタマー及びその使用 |
| WO2014116789A1 (en) * | 2013-01-25 | 2014-07-31 | Thymon, Llc | Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection |
| KR102394676B1 (ko) * | 2014-03-24 | 2022-05-09 | 가부시키가이샤 리보믹 | Fgf2에 대한 압타머 및 그의 사용 |
| WO2015200539A1 (en) * | 2014-06-25 | 2015-12-30 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| JP2018124390A (ja) | 2017-01-31 | 2018-08-09 | 株式会社沖データ | 画像形成装置及び定着制御方法 |
-
2019
- 2019-06-28 BR BR112020026634-5A patent/BR112020026634A2/pt not_active Application Discontinuation
- 2019-06-28 AU AU2019292134A patent/AU2019292134B2/en active Active
- 2019-06-28 CA CA3105002A patent/CA3105002A1/en active Pending
- 2019-06-28 CN CN201980043745.7A patent/CN112384246B/zh active Active
- 2019-06-28 ES ES19825285T patent/ES2992308T3/es active Active
- 2019-06-28 WO PCT/JP2019/025766 patent/WO2020004607A1/ja not_active Ceased
- 2019-06-28 US US17/256,368 patent/US20210269802A1/en active Pending
- 2019-06-28 JP JP2020527674A patent/JP7340264B2/ja active Active
- 2019-06-28 TW TW108122887A patent/TWI845521B/zh active
- 2019-06-28 KR KR1020217002648A patent/KR102841342B1/ko active Active
- 2019-06-28 EP EP19825285.0A patent/EP3815715B1/en active Active
- 2019-06-28 SG SG11202012933QA patent/SG11202012933QA/en unknown
- 2019-06-28 MX MX2020014124A patent/MX2020014124A/es unknown
-
2020
- 2020-12-20 IL IL279595A patent/IL279595B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI845521B (zh) | 2024-06-21 |
| EP3815715B1 (en) | 2024-09-11 |
| ES2992308T3 (es) | 2024-12-11 |
| CA3105002A1 (en) | 2020-01-02 |
| AU2019292134A1 (en) | 2021-02-11 |
| KR20210025083A (ko) | 2021-03-08 |
| EP3815715A4 (en) | 2022-03-16 |
| BR112020026634A2 (pt) | 2021-04-06 |
| IL279595A (en) | 2021-03-01 |
| IL279595B1 (en) | 2025-11-01 |
| EP3815715A1 (en) | 2021-05-05 |
| AU2019292134B2 (en) | 2025-07-10 |
| SG11202012933QA (en) | 2021-01-28 |
| JPWO2020004607A1 (ja) | 2021-07-15 |
| TW202012625A (zh) | 2020-04-01 |
| KR102841342B1 (ko) | 2025-07-31 |
| CN112384246B (zh) | 2025-02-21 |
| JP7340264B2 (ja) | 2023-09-07 |
| EP3815715C0 (en) | 2024-09-11 |
| US20210269802A1 (en) | 2021-09-02 |
| CN112384246A (zh) | 2021-02-19 |
| WO2020004607A1 (ja) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501931A1 (en) | Anti-pdl1 antibody formulations | |
| CY1121928T1 (el) | Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης | |
| CO2019009680A2 (es) | Anticuerpo anti-gprc5d y molécula que comprende el anticuerpo | |
| ZA201706227B (en) | Vaporizer for vaporizing an active ingredient | |
| MX2020004698A (es) | Exosomas que comprenden agentes terapeuticos de arn. | |
| CL2020003174S1 (es) | Dispositivo para administración de dosis. | |
| MY195009A (en) | Cellular Targeted Active Ingredient Delivery System | |
| ECSDI18019182S (es) | Dispositivo intranasal para suministro de fármacos | |
| ECSP15013227A (es) | Formulaciones acuosas estables de adalimumab | |
| MX2020003760A (es) | Formulaciones de niraparib. | |
| CL2015002891A1 (es) | Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales. | |
| CL2015001461A1 (es) | Una formulación estabilizada de pemetrexed. | |
| PH12016500720A1 (en) | Stable formulation of insulin glulisine | |
| BR112017028468A2 (pt) | formulação sólida oral, e método para preparar uma formulação sólida oral | |
| MX2020004424A (es) | Formulacion aerosolizable. | |
| CY1122578T1 (el) | Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα | |
| BR112017024039B8 (pt) | Piroglutamato de vortioxetina, composições farmacêuticas e gel compreendendo o mesmo, método para preparar um gel, e usos do piroglutamato de vortioxetina para fabricação de um medicamento ou gel | |
| MX2019015167A (es) | Farmacos antivirales. | |
| MX2017002737A (es) | Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio. | |
| MX2019010330A (es) | Formulaciones con mejora de la estabilidad. | |
| CY1118277T1 (el) | Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης | |
| MX2020014124A (es) | Preparacion de aptameros. | |
| BR112014011315B8 (pt) | uso de um composto como agente terapêutico para artrose | |
| CL2016001995A1 (es) | Sistemas de suministro de herbicidas sólidos estables | |
| MX2020004245A (es) | Estabilizador mejorado para poliamidas. |